



Guest Editors

Anne-Marie C. Dingemans

Anne-Marie C. Dingemans has been associate professor of pulmonology at the Maastricht University Medical Center (Maastricht, the Netherlands) since 2004, where she currently she coordinates clinical lung cancer trials and is involved in translational research on lung cancer.

Anne-Marie Dingemans received her medical degree at Maastricht University (Maastricht) in 1994 and subsequently her PhD at VU Medical Center (Amsterdam, the Netherlands) in 2000 for laboratory research on resistance to chemotherapy in lung cancer. She performed her training as a pulmonologist at VU Medical Center and at Leiden University Medical Center (Leiden, the Netherlands).

Anne-Marie is a board member of the Netherlands Respiratory Society (NRS) and the secretary of the NVALT studies foundation. She is also a member of the Lung and Other Thoracic Tumours faculty of the European Society for Medical Oncology (ESMO), and of the Harmonised Education in Respiratory Medicine for European Specialists (HERMES) Thoracic Oncology task force. Anne-Marie is a member of the American Association of Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC) and the European Thoracic Oncology Platform (ETOP). She has (co)-authored more than 80 publications and book chapters.



Martin Reck

Martin Reck is head of the Department of Thoracic Oncology and head of the Clinical Trial Department in the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf (Grosshansdorf, Germany). He is also Principal Investigator at the Airway Research Center North (ARCN) (Lung Clinic Grosshansdorf), which is a member of the German Centre for Lung Research (DZL).



Martin Reck underwent medical training at the University of Hamburg (Hamburg, Germany) from 1986–1993. He completed his doctorate at the General Hospital Wandsbek, Hamburg, in 1995, and received post-graduate training at the Hospital Grosshansdorf. He was appointed as a specialist in internal medicine in 2001 and as a specialist in pulmonology in 2002. In 2008, he was awarded a post-doctoral lecturing qualification by the University of Schleswig-Holstein (Kiel, Germany).

Martin Reck has acted as a Principal Investigator or Co-Principal Investigator in various clinical trials since 1993. His main interests are new medical treatments for thoracic malignancies and translational research related to predictive markers. A particular focus of his work is the clinical development of antiangiogenic compounds, such as bevacizumab, nintedanib and other compounds. Recently, he also has been deeply involved in several key trials with immunotherapies, including ipilimumab, programmed cell death protein-1 and programmed cell death ligand-1 antibodies and other agents.

In addition to the International Association for the Study of Lung Cancer (IASLC), Martin Reck is also a member of the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the German Working Group for Lung Cancer, the German Cancer Society (DKG) and the German Respiratory Society (DGP). He has published papers in numerous peer-reviewed journals and is member of the Editorial Boards of the *Journal of Thoracic Oncology*, *Annals of Oncology* and *Lung Cancer*.

Virginie Westeel



Virginie Westeel is professor of pulmonology at the University of Franche-Comté (Besançon, France) and head of the Thoracic Oncology unit at the University Hospital of Besançon (Besançon).

She is a graduate of the University of Franche-Comté. Her clinical and research activities are exclusively dedicated to lung cancer and her research interests include lung cancer therapeutics, follow-up and evidence-based medicine.

Virginie Westeel is currently the Principal Investigator of the only large multicentre randomised trial that has been conducted to date on follow-up after lung cancer surgery. Her 93 publications mostly include the results of clinical trials in both early stage and advanced lung cancer.

Virginie Westeel took on the role of Joint Coordinating Editor of the Cochrane Lung Cancer Review Group in 2013. She led the

development of the French guidelines for lung cancer staging. She has been a member of the scientific committee of the French research group, the Intergroupe Francophone de Cancérologie Thoracique (IFCT), from 2009 to 2013, and she is currently a member of the executive committee of IFCT. Virginie was also a member of the scientific committee of IASLC between 2005 and 2009, and of the scientific committee of several World Conference on Lung Cancer (WCLC). She is a member of the American Society of Clinical Oncology (ASCO) and the International Association for the Study of Lung Cancer (IASLC).